179324-69-7 Bortezomib AKSci Q425
 
 
Loading Please Wait...
  Q425    AKSci Reference Standard
Bortezomib
, 98%, powder
 
MG-341
PS-341




IDENTITY
CAS Number:179324-69-7
MDL Number:MFCD09056737
MF:C19H25BN4O4
MW:384.24
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:98%, powder
Physical Form (at 20°C):Solid
Melting Point:139-143°C
Density:1.214
Long-Term Storage:Store long-term at -20°C
DOT/IATA TRANSPORT INFORMATION
UN #:UN3249
Hazard Class:6.1; Poison
Packing Group:II
A hazmat fee may apply to certain package sizes. Please check pricing table for an indicator of applicable hazmat fees.

BIOLOGICAL INFO
Solubility:DMSO
Application(s):Proteasome inhibitor
Form:Free base
Research Area:solid tumours, non-small cell lung cancer

REVIEW

 Bortezomib is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. As a dipeptide boronic acid analog with antineoplastic activity, Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor NF-κB, a protein that is constitutively activated in some cancers, thereby interfering with NF-κB -mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.

REFERENCES
[1]Janca, Michal; Dobrovolny, Petr Preparation of bortezomib, a boronic acid dipeptide PCT Int. Appl. (2009), WO 2009004350 A1 20090108.
[2] Palle, Raghavendracharyulu Venkata; Kadaboina, Rajasekhar; Murki, Veerender; Manda, Amarendhar; Gunda, Nageshwar; Pulla, Ramaseshagiri Rao; Hanmanthu, Mallesha; Mopidevi, Narasimha Naidu; Ramdoss, Suresh Kumar Preparation of bortezomib in crystalline form PCT Int. Appl. (2009), WO 2009036281 A2 20090319.
[3] Zhu, Yongqiang; Zhao, Xin; Zhu, Xinrong; Wu, Gang; Li, Yuejie; Ma, Yuheng; Yuan, Yunxia; Yang, Jie; Hu, Yang; Ai, Li; et al Design, Synthesis, Biological Evaluation, and Structure-Activity Relationship (SAR) Discussion of Dipeptidyl Boronate Proteasome Inhibitors, Part I: Comprehensive Understanding of the SAR of a-Amino Acid Boronates Journal of Medicinal Chemistry (2009), 52(14), 4192-4199.
[4] Milo, Lawrence J.; Lai, Jack H.; Wu, Wengen; Liu, Yuxin; Maw, Hlaing; Li, Youhua; Jin, Zhiping; Shu, Ying; Poplawski, Sarah E.; Wu, Yong; et al Chemical and Biological Evaluation of Dipeptidyl Boronic Acid Proteasome Inhibitors for Use in Prodrugs and Pro-Soft Drugs Targeting Solid Tumors Journal of Medicinal Chemistry (2011), 54(13), 4365-4377.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H300; H310; H330; H372

Precautionary Statements
P260; P284; P301+P310; P304+P340; P320; P330; P361; P302+P350; P405; P501


RELATED PRODUCTS
Q425Bortezomib
X1030N-(Pyrazinylcarbonyl)-L-phenylalanine

Current as of April 25, 2024

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.



CATEGORIES

 APIs and Bioactives > Chemotherapeutics


PubChem